Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure
- PMID: 22813604
- DOI: 10.1016/j.jacc.2012.05.005
Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure
Abstract
This review provides the rationale for integrating genomic and protein biomarkers in the evolving diagnosis and management of dilated cardiomyopathy (DCM) and its causal pathway to heart failure (HF), with a larger objective to serve as a template for genomic and phenomic profiling of other cardiovascular disease. DCM is a major cause of HF and accounts for more than half of heart transplantation in adults and children worldwide. DCM may remain asymptomatic for years, but HF and/or arrhythmias, both late manifestations of the disease, ultimately cause significant morbidity and mortality. A significant proportion of DCM has a genetic etiology. DCM can also result from environmental injury such as infection, toxins, or catecholamine excess. While molecular genetic testing can identify those at risk for genetic DCM, epigenetic and sentinel phenomic staging can help to identify those at highest risk in need for intervention. Phenomic staging includes integrating clinical and imaging features, transcriptomics, higher order proteomics and metabolomics interactions, and epidemiological data. This principle can be applied in family members of patients with DCM, where genetic testing and clinical phenotyping are indicated. This will allow the design of specific interventions tailored to individuals sharing similar risks, to alter the natural history of DCM and obviate complications such as HF/arrhythmias.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
[Familial dilated cardiomyopathy].Herz. 2005 Sep;30(6):529-34. doi: 10.1007/s00059-005-2732-3. Herz. 2005. PMID: 16170685 Review. German.
-
Clinical and Genetic Investigations of 109 Index Patients With Dilated Cardiomyopathy and 445 of Their Relatives.Circ Heart Fail. 2020 Oct;13(10):e006701. doi: 10.1161/CIRCHEARTFAILURE.119.006701. Epub 2020 Oct 6. Circ Heart Fail. 2020. PMID: 33019804
-
Energy Metabolites as Biomarkers in Ischemic and Dilated Cardiomyopathy.Int J Mol Sci. 2021 Feb 18;22(4):1999. doi: 10.3390/ijms22041999. Int J Mol Sci. 2021. PMID: 33670449 Free PMC article.
-
Epigenome-Wide Association Study Identifies Cardiac Gene Patterning and a Novel Class of Biomarkers for Heart Failure.Circulation. 2017 Oct 17;136(16):1528-1544. doi: 10.1161/CIRCULATIONAHA.117.027355. Epub 2017 Aug 24. Circulation. 2017. PMID: 28838933
-
Genetics of dilated cardiomyopathy.Heart Fail Clin. 2010 Apr;6(2):129-40. doi: 10.1016/j.hfc.2009.11.003. Heart Fail Clin. 2010. PMID: 20347783 Review.
Cited by
-
Familial dilated cardiomyopathy. Clinical and genetic characteristics.Herz. 2012 Dec;37(8):822-9. doi: 10.1007/s00059-012-3707-9. Herz. 2012. PMID: 23223770
-
Genetics and genetic testing of dilated cardiomyopathy: a new perspective.Discov Med. 2013 Jan;15(80):43-9. Discov Med. 2013. PMID: 23375013 Free PMC article. Review.
-
Stratification of the risk of sudden death in nonischemic heart failure.Arq Bras Cardiol. 2014 Oct;103(4):348-57. doi: 10.5935/abc.20140125. Epub 2014 Aug 29. Arq Bras Cardiol. 2014. PMID: 25352509 Free PMC article. Review.
-
Dystrophic Cardiomyopathy: Complex Pathobiological Processes to Generate Clinical Phenotype.J Cardiovasc Dev Dis. 2017 Sep 8;4(3):14. doi: 10.3390/jcdd4030014. J Cardiovasc Dev Dis. 2017. PMID: 29367543 Free PMC article. Review.
-
The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy.Can J Cardiol. 2015 Nov;31(11):1309-12. doi: 10.1016/j.cjca.2015.06.034. Epub 2015 Jul 9. Can J Cardiol. 2015. PMID: 26518443 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous